Keros Therapeutics (KROS) Outperform Rating Reiterated at Wedbush theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Wells Fargo & Company assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report report published on Friday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $60.00 target price on the stock. Separately, Wedbush reiterated an outperform rating and issued a $86.00 price objective on shares […]
Keros Therapeutics, Inc (NASDAQ:KROS) Given Consensus Rating of Buy by Analysts etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has been assigned a consensus rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock […]
Candriam S.C.A. lifted its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) by 19.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 745,057 shares of the company’s stock after buying an additional 119,143 shares during the quarter. Candriam S.C.A.’s holdings in Keros Therapeutics […]